Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, Chi A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.Peer-Reviewed Original ResearchMeSH KeywordsGlioblastomaImmunotherapyLab-On-A-Chip DevicesProgrammed Cell Death 1 ReceptorTumor MicroenvironmentConceptsProgrammed cell death protein 1Immunosuppressive tumor microenvironmentTumor-associated macrophagesTumor microenvironmentCD163+ tumor-associated macrophagesPD-1/PD-L1 immune checkpointCSF-1R inhibitor BLZ945Molecularly distinct GBM subtypesCell death protein 1Anti-PD-1 immunotherapyT cell functionNivolumab efficacyImmunotherapy efficacyImmune checkpointsImmune signaturesImmunosuppressive mechanismsT cellsM2-TAMsCo-administeredGlioblastoma patientsIL-10CSF-1RCSF-1ImmunotherapyProneural glioblastomaRacial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma
Liu E, Yu S, Sulman E, Kurz S. Racial and socioeconomic disparities differentially affect overall and cause-specific survival in glioblastoma. Journal Of Neuro-Oncology 2020, 149: 55-64. PMID: 32617722, DOI: 10.1007/s11060-020-03572-y.Peer-Reviewed Original ResearchConceptsCause-specific mortalityMedian household incomeNational Cancer Institute's SurveillanceHousehold incomeCalendar year of diagnosisAssociated with all-cause mortalityNon-Hispanic whitesMethodsThe National Cancer Institute’s SurveillanceAll-cause mortalityCox proportional hazards modelsYear of diagnosisSocioeconomic disparitiesProportional hazards modelAsian/Pacific IslanderInstitute's SurveillanceHispanic whitesSocioeconomic groupsTreatment receiptPatient raceNon-glioblastomaCohort dataSocioeconomic factorsCause-specific mannerInclusion criteriaBlack raceNovel Therapies for Glioblastoma
Liu E, Sulman E, Wen P, Kurz S. Novel Therapies for Glioblastoma. Current Neurology And Neuroscience Reports 2020, 20: 19. PMID: 32445058, DOI: 10.1007/s11910-020-01042-6.Peer-Reviewed Original ResearchConceptsClinical studiesEarly phase clinical studiesNovel radiotherapy approachesSignificant survival benefitMalignant primary brain tumorPhase clinical studiesPersonalized treatment approachesDiverse resistance mechanismsPrimary brain tumorCheckpoint inhibitionRadiotherapy optionsRadiotherapy approachesDose deliveryRadiation modalitiesSurvival benefitBiomarker-drivenTargeted therapyTargeted agentsTreatment optionsNovel therapiesTumor heterogeneityClinical investigationVaccination strategiesBrain tumorsTreatment approaches